Adaptive Biotechnologies is trading 4.13% higher at $24.57, with broader biotech-sector strength providing the clearest available explanation.
- XBI is up 2.09%, while renewed merger-and-acquisition speculation is supporting industry sentiment.
- No new company-specific announcement was identified for August 7, 2026.
- The latest major company event remains the July 29 earnings report, which included higher revenue and raised MRD guidance.